These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 30623359)

  • 1. Biological Products: Cellular Therapy and FDA Approved Products.
    Golchin A; Farahany TZ
    Stem Cell Rev Rep; 2019 Apr; 15(2):166-175. PubMed ID: 30623359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Regulatory science research to facilitate the development of cell/tissue-processed products].
    Sato Y; Tsutsumi H; Sawada R; Suzuki T; Yasuda S
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):16-9. PubMed ID: 24340665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDA and NIST collaboration on standards development activities supporting innovation and translation of regenerative medicine products.
    Arcidiacono JA; Bauer SR; Kaplan DS; Allocca CM; Sarkar S; Lin-Gibson S
    Cytotherapy; 2018 Jun; 20(6):779-784. PubMed ID: 29784433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regenerative Medicine: Injectable Cell-Based Therapeutics and Approved Products.
    Golchin A; Shams F; Kangari P; Azari A; Hosseinzadeh S
    Adv Exp Med Biol; 2020; 1237():75-95. PubMed ID: 31302869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of Regenerative Medicine Products.
    Gee AP
    Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?
    Yano K; Speidel AT; Yamato M
    J Tissue Eng Regen Med; 2018 Jul; 12(7):1579-1593. PubMed ID: 29702746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Trends in Clinical Development of Gene and Cellular Therapeutic Products for Cancer in Japan.
    Nagai S; Sugiyama D
    Clin Ther; 2019 Jan; 41(1):174-184.e3. PubMed ID: 30528048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balancing Safety and Innovation for Cell-Based Regenerative Medicine.
    Marks P; Gottlieb S
    N Engl J Med; 2018 Mar; 378(10):954-959. PubMed ID: 29514023
    [No Abstract]   [Full Text] [Related]  

  • 9. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
    Sato Y
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. United States Food and Drug Administration Regulation of Gene and Cell Therapies.
    Bailey AM; Arcidiacono J; Benton KA; Taraporewala Z; Winitsky S
    Adv Exp Med Biol; 2015; 871():1-29. PubMed ID: 26374210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA faces regulatory challenges with new approaches to medicine.
    Roehr B
    BMJ; 2014 Feb; 348():g1530. PubMed ID: 24531207
    [No Abstract]   [Full Text] [Related]  

  • 12. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
    Knoepfler PS
    Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving regulatory landscape in regenerative medicine.
    Beetler DJ; Di Florio DN; Law EW; Groen CM; Windebank AJ; Peterson QP; Fairweather D
    Mol Aspects Med; 2023 Jun; 91():101138. PubMed ID: 36050142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artificial intelligence: A joint narrative on potential use in pediatric stem and immune cell therapies and regenerative medicine.
    Sniecinski I; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):422-424. PubMed ID: 29784537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan.
    Nagai S
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31382625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US FDA outreach to the regenerative medicine community: challenges and opportunities.
    Whittlesey KJ; Witten C
    Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genome Editing Techniques and Their Therapeutic Applications.
    Calos MP
    Clin Pharmacol Ther; 2017 Jan; 101(1):42-51. PubMed ID: 27783398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concise Review: The U.S. Food and Drug Administration and Regenerative Medicine.
    Witten CM; McFarland RD; Simek SL
    Stem Cells Transl Med; 2015 Dec; 4(12):1495-9. PubMed ID: 26494784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping and driving the stem cell ecosystem.
    Knoepfler PS
    Regen Med; 2018 Oct; 13(7):845-858. PubMed ID: 30289055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon.
    Mendicino M; Fan Y; Griffin D; Gunter KC; Nichols K
    Cytotherapy; 2019 Jul; 21(7):699-724. PubMed ID: 31196820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.